M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine

Phase 3

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: educational intervention
Other: questionnaire administration

First Posted Date: 2008-02-06

Last Posted Date: 2020-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1356

Registration Number: NCT00608933

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma

Interventions: Drug: Avastin
Drug: RAD001

First Posted Date: 2008-02-05

Last Posted Date: 2013-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00607113

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Social-Psychological Aspects of Orbital Exenteration

Completed

Conditions: Eye Cancer

Interventions: Behavioral: Audio-Taped Interview
Behavioral: Questionnaire

First Posted Date: 2008-01-28

Last Posted Date: 2013-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00601744

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Function and Balance for Inpatient Rehabilitation

Completed

Conditions: Solid Tumors

Interventions: Other: Walking Test
Other: Balance Test
Behavioral: Questionnaire
Behavioral: Diary

First Posted Date: 2008-01-25

Last Posted Date: 2013-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00601133

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Whole Body Magnetic Resonance Imaging (MRI) for Detection of Cancer Metastases

Completed

Conditions: Breast Cancer

Interventions: Procedure: Whole Body MRI

First Posted Date: 2008-01-14

Last Posted Date: 2016-10-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00592462

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

Phase 2

Completed

Conditions: Lymphoma
Diffuse Large Cell Lymphoma

Interventions: Drug: Zevalin
Drug: Carmustine
Drug: Etoposide
Drug: Cytarabine
Drug: Melphalan
Drug: Rituximab
Procedure: Stem Cell Transplant

First Posted Date: 2008-01-11

Last Posted Date: 2021-02-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00591630

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carotid Artery Disease in Childhood Cancer Survivors

Terminated

Conditions: Pediatric Cancers

Interventions: Procedure: Carotid Ultrasound

First Posted Date: 2008-01-11

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00591539

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Combined Treatment for Tobacco and Alcohol Use

Not Applicable

Withdrawn

Conditions: Smoking Cessation

Interventions: Behavioral: Questionnaires
Behavioral: Motivational Relapse Prevention Counseling
Behavioral: Relapse Plus Alcohol Risk Reduction Counseling

First Posted Date: 2008-01-11

Last Posted Date: 2016-07-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00592085

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Docetaxel
Drug: Gemcitabine
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2007-12-31

Last Posted Date: 2013-05-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00583622

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Testosterone in Castration-Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Testosterone

First Posted Date: 2007-12-20

Last Posted Date: 2013-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00577980

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy